Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics ...
Active drug shortages in the U.S. rose for the second consecutive quarter in 2026, reaching 223 in the first quarter, according to a recent report from the American Society of Health-System ...
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has ...
Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report tied to the ...
Lupron Depot (leuprolide acetate) is a brand-name injection prescribed for prostate cancer and other hormone-related conditions. Lupron Depot’s side effects may vary depending on the dosage and the ...
Investor's Business Daily on MSN
Novo Nordisk Jumps On 'Strongest-Ever' Launch In Weight Loss
Novo Nordisk stock jumped early Wednesday on a strong first-quarter report on the back of its GLP-1 drugs Wegovy and Ozempic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results